Last Updated: November 16, 2026

Protein c concentrate (human) - Biologic Drug Details

« Back to Dashboard


Summary for protein c concentrate (human)
Tradenames:1
High Confidence Patents:1
Applicants:1
BLAs:1
Suppliers: see list1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for protein c concentrate (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for protein c concentrate (human) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Takeda Pharmaceuticals U.s.a., Inc. CEPROTIN protein c concentrate (human) For Injection 125234 5,549,893 2015-04-27 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for protein c concentrate (human) Derived from Patent Text Search

These patents were obtained by searching patent claims
Last updated: June 3, 2026

Market dynamics and financial trajectory for protein C concentrate (human) biologic drug

Protein C concentrate (human) is a niche, high-acuity biologic with constrained addressable demand, episodic patient flows tied to congenital Protein C deficiency and acquired consumptive coagulopathies, and pricing shaped by hospital formularies and payer prior authorization. Financial trajectory is dominated by: (1) U.S. regulatory/commercial life-cycle position and supply continuity risk, (2) litigation and exclusivity events that alter competitive entry timing, and (3) global purchasing behavior for rare-disease and critical-care products. On the balance of observable market structure for Protein C concentrate (human), revenue is typically driven more by replacement demand and acute-care utilization than by durable, broad chronic uptake.

What is protein C concentrate (human) used for, and how does that drive demand?

Protein C concentrate (human) is used to restore Protein C activity in patients with Protein C deficiency and Protein C dysfunction states. Demand is concentrated in hospitals and intensive care settings where clinicians manage thrombosis risk, severe coagulopathy, and neonatal/critical care use cases.

Which patient groups create recurring volume?

  • Congenital Protein C deficiency (pediatric and adult thrombosis prevention and treatment).
  • Acquired severe Protein C deficiency in specific consumptive coagulopathy contexts where Protein C activity is profoundly reduced.
  • Neonatal thrombosis risk management in selected scenarios where clinicians use Protein C replacement to mitigate thrombotic complications.

How “acute” usage affects revenue stability

  • Treatment is episode-based: patients receive dosing during acute events rather than continuous, large-population therapy.
  • Hospital procurement cycles and case volumes govern year-to-year fluctuations.
  • Product switching can occur when institutions revise thrombosis protocols or when competing products change availability or pricing.

How big is the addressable market for human protein C concentrate, and what caps growth?

The core limitation is epidemiology. Congenital Protein C deficiency is rare, and acquired use cases are conditional on specific clinical phenotypes and severity. As a result, the addressable market is narrower than broad thrombosis therapeutics (eg, anticoagulants).

What market segments matter most commercially?

  • High-acuity centers with neonatal intensive care units and hematology services.
  • Tertiary hospitals with thrombosis programs and established rare-disease formularies.
  • Specialty distributors serving hemophilia and rare coagulation supply chains.

What growth levers exist

  • More conservative adoption of Protein C replacement in severe neonatal or consumptive coagulopathy guidelines can add incremental demand.
  • Improved diagnosis rates and greater clinician familiarity can increase case capture.
  • Expansion into geographies where supply access remains inconsistent can shift volume, but it is constrained by reimbursement approval timelines and procurement processes.

Who are the main competitors to protein C concentrate (human), and how do their positions change market share?

Protein C concentrate (human) competes within a narrow biologics space where substitution is limited because clinicians prioritize demonstrated Protein C activity restoration and product-specific dosing/administration characteristics. Competitive pressure tends to come through:

  • Alternative Protein C concentrate products (if available in a given geography).
  • Differing supply reliability and pricing terms that influence hospital formulary inclusion.
  • Biosimilar-type competition is not typically the primary dynamic here; the key risk is entry of other plasma-derived Protein C concentrate products or regulatory approvals in additional markets.

What usually drives share shifts in this market

  • Supply continuity and lead times for plasma-derived products.
  • Contracting outcomes in group purchasing organizations and national tenders.
  • Outcomes data from real-world use that affect clinician trust and protocol adoption.
  • Pricing concessions tied to budget impact in rare-disease and hospital pharmacy procurement.

What drives pricing and contracting for protein C concentrate (human) at the hospital and payer level?

Pricing is structurally shaped by:

  • Rare-disease premium dynamics and payer willingness to cover high-cost therapy when criteria are met.
  • Prior authorization and center-of-excellence requirements.
  • Hospital procurement negotiating leverage based on annual patient counts and substitution alternatives.

Where reimbursement bottlenecks appear

  • Medical benefit coverage, often requiring documentation of Protein C deficiency phenotype and severity.
  • Off-label use constraints if payer policies are strict.
  • Coverage gaps for neonates or specific acquired indications depending on payer policy language.

How contract terms affect the financial trajectory

  • Net price can differ materially from list price due to rebates, channel discounts, and patient assistance structures.
  • Contract renewals can trigger step changes in net revenue if formulary access is renegotiated.

When does protein C concentrate (human) lose exclusivity, and how does that affect generics and biosimilar risk?

Protein C concentrate (human) is a biologic that typically has product-specific exclusivity and patent estates tied to manufacturing processes, formulations (presentation), and use claims. The exclusivity timeline determines whether additional Protein C concentrate offerings can enter without full payer and prescriber disruption.

What to track for exclusivity and entry risk

  • Expiration of composition-of-matter and process patents.
  • Expiration of formulation and device/administration related patents (if listed).
  • Any regulatory exclusivity that blocks follow-on competition.
  • Litigation that can delay market entry or impose licensing terms.

How follow-on entry would likely play out commercially

  • Initial entry in limited geographies with cautious contracting.
  • Higher administrative burden on hospitals to switch protocols.
  • Revenue impacts concentrate first at hospitals that reopen formularies after entry.

What patent landscape covers protein C concentrate (human), and which claims most influence competition?

For Protein C concentrate (human), patent estates commonly include:

  • Plasma fractionation and purification processes.
  • Viral inactivation steps and clearance validation methods.
  • Formulation and stabilization approaches.
  • Potential method-of-use claims for specific deficiency states or clinical protocols.

How patent strength maps to commercial risk

  • Process patents can limit manufacturing replication even when product is conceptually similar.
  • Formulation patents can affect product substitution because clinicians expect consistent reconstitution and activity profiles.
  • Method-of-use patents matter if payer coverage or off-label protocols become tied to patented clinical endpoints.

What litigation and settlement events have affected protein C concentrate (human) entry timing?

Litigation in this niche market tends to affect:

  • Competitor approval-to-commercialization timing.
  • Licensing terms that determine net pricing and channel inclusion.
  • Supply launch sequencing and hospital contracting windows.

How disputes show up in financial results

  • Delays can extend higher-margin protected periods.
  • Settlements can introduce a “licensed competitor” that reduces share and triggers pricing pressure.
  • Court or regulatory outcomes can shift investor expectations for revenue durability.

What is the FDA regulatory status of protein C concentrate (human), and how does it shape market dynamics?

Protein C concentrate (human) is regulated as a biologic product. FDA status affects:

  • Market access cadence (initial approval and supplemental approvals).
  • Label scope, which directly shapes reimbursable indications and formulary demand.
  • Manufacturing comparability expectations and ongoing lot release constraints.

What regulatory events typically shift revenue

  • Label expansions that broaden covered populations.
  • Manufacturing changes that trigger post-approval compliance scrutiny.
  • Supply interruptions due to manufacturing facility constraints or lot acceptance issues.

What formulations, dosing presentations, and manufacturing constraints matter commercially?

Revenue in Protein C concentrate is highly sensitive to the operational realities of plasma-derived biologics.

What matters in purchasing decisions

  • Packaging and reconstitution workflow for hospital pharmacy utilization.
  • Cold-chain or storage constraints for ED and ICU settings.
  • Availability lead time and safety stock planning.

How manufacturing constraints affect financial trajectory

  • Shortages reduce administered volume and can shift patients to alternative therapies.
  • Lot rejections reduce fill rate and can depress net revenue for a period.
  • Quality events can force temporary reductions in shipments, elevating distributor carrying costs.

How does protein C concentrate (human) compare with alternative coagulation therapies in cost-effectiveness dynamics?

The commercial choice set usually includes:

  • Anticoagulants for thrombosis risk.
  • Supportive management and replacement strategies.
  • Alternative plasma-derived or replacement therapies if available in the same care settings.

Why Protein C concentrate can still win despite rare use

  • Potential to reduce thrombotic complications in targeted phenotypes.
  • ICU workflows favor therapies with predictable mechanistic impact on Protein C activity.
  • Hospitals may accept high unit costs when patient-specific need is strong and outcomes are clinically meaningful.

What revenue exposure risks exist for the current protein C concentrate (human) commercial owner?

Primary revenue risks:

  • Supply and lot release risk for plasma-derived products.
  • Contract repricing and formulary reversion in high-discount procurement environments.
  • Patent challenge outcomes and potential follow-on entry.
  • Label limitations or payer policy tightening that reduces reimbursable patient pools.
  • Manufacturing disruptions that lead to fill failures and lost administrations.

Market scenario analysis: what happens to the financial trajectory under entry or shortage?

If follow-on competition enters

  • Net price likely declines as hospitals diversify suppliers.
  • Revenue growth slows and becomes more replacement-driven.
  • Contracting shifts from “preferred supplier” to “two- or three-way” sourcing.

If shortages persist

  • Fill rate drives revenue rather than demand.
  • Hospitals may ration or shift patients, creating permanent loss of administered volumes.
  • Distributor relationships can break if lead times worsen, affecting future contracting.

If label scope expands

  • Capturable addressable patients increase.
  • Payer coverage may lag, but hospitals with high acute-care throughput can capture faster adoption.

Key Takeaways

  • Protein C concentrate (human) is a niche biologic with episode-based, hospital-centered demand driven by rare congenital deficiency and conditional acquired Protein C deficiency states.
  • Financial trajectory is shaped less by broad market growth and more by exclusivity/patent duration, supply continuity, and payer contracting outcomes.
  • Revenue durability is sensitive to patent-driven entry risk, and upside is tied to label scope and guideline-driven adoption.
  • The dominant operational lever is manufacturing and lot availability for plasma-derived supply, which can swing quarterly revenue through fill-rate effects.

FAQs

1) How do hospital formulary and prior authorization requirements influence protein C concentrate net revenue?

Net revenue is determined by contracting outcomes, medical benefit coverage criteria, and documentation of Protein C deficiency phenotype and severity, which can limit reimbursable volumes even when clinical need exists.

2) Does patent expiration for protein C concentrate usually impact pricing before clinical guidelines change?

Yes. Exclusivity and patent estate events can enable new suppliers earlier than guidelines shift, causing payers and hospitals to renegotiate pricing and sourcing immediately.

3) What is the biggest operational driver of quarterly revenue for protein C concentrate products?

Lot release and supply continuity, including manufacturing uptime and fill rates, typically dominate quarter-to-quarter performance for plasma-derived biologics.

4) Are method-of-use patents more commercially important than process patents for protein C concentrate?

Usually process patents are commercially significant because they can constrain manufacturing replication, while method-of-use patents matter when payer policy or prescribing practices track patented clinical claims.

5) How would a product shortage affect long-term market share for protein C concentrate?

Shortages can lead to protocol shifts and supplier diversification at hospitals, creating durable volume loss even after supply normalizes.

References

  1. FDA. Licensed Biological Products: Guidance for Industry. U.S. Food and Drug Administration.
  2. FDA. Drug Development and Drug Interactions: Orange Book and exclusivity concepts. U.S. Food and Drug Administration.
  3. EMA. Guideline on the quality, non-clinical and clinical aspects of similar biological medicinal products containing biotechnology-derived proteins as active substance. European Medicines Agency.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.